SynthesisFrontiers in oncology2026
The effect of PARP inhibitor-based targeted therapy on BRCA-mutated ovarian cancer: systematic literature review.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ovarian cancer remains one of the leading causes of gynecologic cancer mortality worldwide, largely due to late-stage diagnosis and high recurrence rates. Mutations in the BRCA1 and BRCA2 genes disrupt homologous recombination repair pathways, creating a therapeutic vulnerability that can be exploited by poly (ADP-ribose) polymerase (PARP) inhibitors. Although PARP inhibitors have demonstrated clinical benefits in BRCA-mutated ovarian cancer, variability across clinical studies has led to uncertainty regarding their overall effectiveness and long-term outcomes. Objectives: This study aimed to systematically evaluate the efficacy and safety of PARP inhibitor-based therapy in patients with BRCA-mutated ovarian cancer. Methods: A systematic literature review and meta-analysis were conducted following PRISMA 2020 guidelines. Four electronic databases (PubMed, Scopus, EMBASE, and Cochrane Library) were searched for studies published between 2013 and 2025. Eligible studies included randomized controlled trials and observational cohort studies evaluating PARP inhibitors in patients with BRCA-mutated ovarian cancer. Risk of bias was assessed using the Cochrane Risk of Bias Tool and the Newcastle-Ottawa Scale. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a meta-analytic approach. Results: Twelve studies met the inclusion criteria for qualitative synthesis, including five randomized controlled trials and seven observational cohort studies. Four studies were eligible for quantitative meta-analysis. PARP inhibitor therapy significantly improved progression-free survival (PFS) (HR: 0.62, 95% CI: 0.56-0.68). In contrast, improvement in overall survival (OS) was modest (HR: 0.82, 95% CI: 0.68-0.98) and less consistently reported. Hematologic toxicities, particularly anemia and thrombocytopenia, were the most frequently reported grade ≥3 adverse events. Conclusion: PARP inhibitors provide a significant progression-free survival benefit in patients with BRCA-mutated ovarian cancer, particularly when used as maintenance therapy. However, the impact on overall survival remains uncertain, highlighting the need for longer follow-up and further prospective studies to optimize treatment strategies and clarify long-term clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.